Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the ...
Drugs targeting mutations in the anaplastic lymphoma kinase gene (ALK) are already useful in lung cancer, but they may also find a use in the treatment of leukemias. ALK mutations were found in two ...
Zidesamtinib is a novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain ...
Nuvalent seeks FDA approval of neladalkib for TKI-pretreated advanced ALK-positive NSCLC, leveraging ALKOVE-1 results demonstrating activity in extracranial disease and brain metastases. ALKOVE-1 ...
Please provide your email address to receive an email when new articles are posted on . Alectinib significantly improved DFS in patients with completely resected ALK-positive NSCLC compared with ...
TRIANA announces one oral and three poster presentations for its clinical asset, TRI-611, and its preclinical asset CCNE1 at the AACR Meeting 2026 ...
Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ...
FDA fast track designation applies to ALK+ NSCLC progressing after ≥2 ALK TKIs, reflecting limited post-lorlatinib therapeutic options and enabling more frequent FDA interactions and potential rolling ...
Quantifying clinical harm and financial waste from failure to deploy personalized medicine for patients with metastatic non-small cell lung cancer in the United States. This is an ASCO Meeting ...
MADRID -- Disease-free survival (DFS) in resectable ALK-positive non-small cell lung cancer (NSCLC) improved by 76% with adjuvant alectinib (Alecensa) compared with chemotherapy, according to a ...
An anaplastic lymphoma kinase (ALK)-targeted agent induced high response rates for adults with ALK-positive anaplastic large cell lymphoma (ALCL) who had failed on brentuximab vedotin (Adcetris), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results